RT Journal Article
SR Electronic
T1 Target attainment of extended-interval dosing of tobramycin in patients less than five years of age with cystic fibrosis: A pharmacokinetic analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.02.22268643
DO 10.1101/2022.01.02.22268643
A1 Downes, Kevin J
A1 Grim, Austyn
A1 Shanley, Laura
A1 Rubenstein, Ronald C
A1 Zuppa, Athena F
A1 Gastonguay, Marc R.
YR 2022
UL http://medrxiv.org/content/early/2022/01/03/2022.01.02.22268643.abstract
AB Background Extended interval dosing (EID) of tobramycin is recommended for treatment of pulmonary exacerbations in adults and older children with cystic fibrosis (CF), but data are limited in patients less than 5 years of age.Methods We performed a retrospective population pharmacokinetic (PK) analysis of hospitalized children with CF <5 years of age prescribed intravenous tobramycin for a pulmonary exacerbation from March 2011 to September 2018 at our hospital. Children with normal renal function who had ≥1 tobramycin concentration available were included. Nonlinear mixed effects population PK modeling was performed using NONMEM® using data from the first 48 hours of tobramycin treatment. Monte Carlo simulations were implemented to determine the fraction of simulated patients that met published therapeutic targets with regimens of 10-15 mg/kg/day once daily dosing.Results Fifty-eight patients received 111 tobramycin courses (range 1-9/patient). A 2-compartment model best described the data. Age, glomerular filtration rate, and vancomycin coadministration were significant covariates on tobramycin clearance. The typical values of clearance and central volume of distribution were 0.252 L/hr/kg^0.75 and 0.308 L/kg, respectively. No once daily regimens achieved all pre-specified targets simultaneously in >75% of simulated subjects. A dosage of 13 mg/kg/dose best met the predefined targets of Cmax >25 mg/L and AUC24 of 80-120 mg*h/L.Conclusions Based on our population PK analysis and simulations, once daily dosing of tobramycin would not achieve all therapeutic goals in young patients with CF. However, extended-interval dosing regimens may attain therapeutic targets in the majority of young patients.Competing Interest StatementAll potential COI has been disclosed in the manuscript.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of the Childrens Hospital of Philadelphia gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsAICAkaike information criterionAUCarea under the concentration-time curveBQLbelow quantification limitCFcystic fibrosisCHOPthe Children’s Hospital of PhiladelphiaCLclearanceCmaxmaximal concentrationCminminimum concentrationDFIdrug-free intervalEIDextended interval dosingIOVinter-occasion variabilityOFVobjective function valuePDpharmacodynamic(s)PKpharmacokinetic(s)Qinter- compartmental clearanceTDMtherapeutic drug monitoringVPCvisual predictive checkV1central volumeV2peripheral volume